Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations
- 1 April 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (7) , 1076-1078
- https://doi.org/10.1097/00002030-200404300-00020
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Relationship between 3′-Azido-3′-Deoxythymidine Resistance and Primer Unblocking Activity in Foscarnet-Resistant Mutants of Human Immunodeficiency Virus Type 1 Reverse TranscriptaseJournal of Virology, 2003
- Phenotypic Mechanism of HIV-1 Resistance to 3‘-Azido-3‘-deoxythymidine (AZT): Increased Polymerization Processivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse TranscriptaseBiochemistry, 1998
- Foscarnet Decreases HIV-1 Plasma LoadJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Pronounced Anti-HIV-1 Activity of Foscarnet in Patients Without Cytomegalovirus InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnetJournal of Virology, 1996
- Foscarnet Decreases Human Immunodeficiency Virus RNAThe Journal of Infectious Diseases, 1995
- Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patientJournal of Medical Virology, 1994